Wound Care Focus ABL Medical markets SilvrSTAT, an antibacterial wound dressing gel indicated for burns, ulcers, skin tears and donor, graft, incision sites. Laboratory tests show activity against microorganisms including antibiotic resistant strains and fungi, with a safety profile reporting no known adverse reactions, making it a compelling option for wound care programs seeking strong antimicrobial coverage.

Regional Expansion Based in Utah with a small to mid size team and a modest revenue profile, ABL Medical has room to scale through strategic distributor partnerships and regional sales efforts. Target hospitals, wound care centers, surgical clinics, and long term care facilities in the western United States to broaden market access.

Blue Light Opportunity ABL Medical has announced the development of antimicrobial blue light fiber technology in collaboration with IlluminOss subsidiary, opening potential for joint product offerings that combine SilvrSTAT dressings with blue light therapies in surgical and orthopedic settings and for infection control programs.

Competitive Differentiation As a smaller innovator with a silver based antimicrobial platform, ABL Medical can differentiate through targeted wound care solutions, flexible product packaging, and rapid adoption into hospital workflows, enabling easier integration into infection control programs and post surgical care.

Partnership Proposals Sales opportunities exist to work with medical distributors serving hospitals, clinics, and wound care networks; explore co marketing with orthopedic, burn, dermatology and dental segments; consider licensing or co development deals to accelerate reach and adoption of SilvrSTAT and future blue light products.